OvaScience is developing and commercializing egg-focused treatment options for women who are facing challenges with their fertility.
Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The OvaScience treatments have the potential to increase IVF success rates by improving egg health, increasing egg reserve and developing the next generation of IVF.
The AUGMENT treatment (launched in certain IVF clinics in select international regions in 2014) is specifically designed to improve a patient’s egg health. Improved egg health may offer the potential for enhanced IVF.
The OvaPrime treatment is a potential fertility option that could enable a woman to increase her egg reserve.
The OvaTure treatment (currently in preclinical development) is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.